Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.74 |
| ▸ | SIK2 | Q9H0K1 | 13/20 | 0.74 |
| ▸ | SIK3 | Q9Y2K2 | 13/20 | 0.74 |
| ▸ | SIK1 | P57059 | 11/20 | 0.74 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.74 |
| ▸ | SRC | P12931 | 6/20 | 0.69 |
| ▸ | BCR | P11274 | 4/20 | 0.68 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.68 |
| ▸ | EGFR | P00533 | 2/20 | 0.68 |
| ▸ | LCK | P06239 | 2/20 | 0.68 |
| ▸ | FYN | P06241 | 2/20 | 0.68 |
| ▸ | CSF1R | P07333 | 2/20 | 0.68 |
| ▸ | YES1 | P07947 | 2/20 | 0.68 |
| ▸ | LYN | P07948 | 2/20 | 0.68 |
| ▸ | RET | P07949 | 2/20 | 0.68 |
| ▸ | HCK | P08631 | 2/20 | 0.68 |
| ▸ | KIT | P10721 | 2/20 | 0.68 |
| ▸ | BRAF | P15056 | 2/20 | 0.68 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.68 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23987821 | 1.00 | ABL1 (0.74) | ABL1SIK2SIK3SIK1PKMYT1 | |
| SCHEMBL31307339 | 0.92 | ABL1 (0.76) | ABL1SIK2SIK3SIK1PKMYT1 | |
| SCHEMBL23987820 | 0.92 | ABL1 (0.76) | ABL1SIK2SIK3SIK1PKMYT1 | |
| SCHEMBL23987824 | 0.91 | PKMYT1 (0.79) | ABL1SIK2SIK3SIK1PKMYT1 | |
| SCHEMBL31307346 | 0.91 | PKMYT1 (0.79) | ABL1SIK2SIK3SIK1PKMYT1 | |
| SCHEMBL31634944 | 0.88 | ABL1 (0.72) | ABL1SIK2SIK3SIK1PKMYT1 | |
| SCHEMBL20537302 | 0.88 | ABL1 (0.72) | ABL1SIK2SIK3SIK1PKMYT1 | |
| SCHEMBL20537284 | 0.86 | PKMYT1 (0.85) | ABL1SIK2SIK3SIK1PKMYT1 | |
| SCHEMBL22964741 | 0.86 | ABL1 (0.84) | ABL1SIK2SIK3SIK1PKMYT1 | |
| SCHEMBL23987822 | 0.85 | ABL1 (0.78) | ABL1SIK2SIK3SIK1PKMYT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101015-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-03-27 | — | — | US | disclosed |
| US-20250084076-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-03-13 | — | — | US | disclosed |
| US-12172993-B2 | Heterocyclic kinase inhibitors and uses thereof | IOMX THERAPEUTICS AG (DE) | 2024-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12172993-B2 | Heterocyclic kinase inhibitors and uses thereof | LCK, SRC, CILK1 | ABL1 8/4885SIK2 25/4885SIK3 46/4885 |
| US-20250101015-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | LCK, SRC, CILK1 | ABL1 8/4885SIK2 25/4885SIK3 46/4885 |
| US-20250084076-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | LCK, SRC, CILK1 | ABL1 8/4885SIK2 25/4885SIK3 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.